- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01326299
Post Prandial Glucose Control Proof-of-Principle
March 29, 2011 updated by: Abbott Nutrition
The purpose of this study is to compare the postprandial glycemic response of subjects with type 2 diabetes when consuming a meal along with beverages containing various combinations of nutritional ingredients and fibers versus control beverage.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45249
- Radiant Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- type 2 diabetes
- between 21 and 75 years of age
- male or a non-pregnant, non-lactating female, at least 6 weeks postpartum or postmenopausal or surgically sterile
- BMI is > 18.5 kg/m2 and <35 kg/m2
- HbA1c < 9.0%
Exclusion Criteria:
- Subject uses exogenous insulin, exenatide, or sitagliptin phosphate
- type 1 diabetes.
- history of diabetic ketoacidosis.
- current infection
- active malignancy
- has had a significant cardiovascular event or history of congestive heart failure.
- end-stage organ failure or post organ transplant.
- history of renal disease.
- hepatic disease.
- history of gastrointestinal disorders
- chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.
- taking any herbals, dietary supplements, or medications, other than oral hypoglycemic medications
- clotting or bleeding disorders.
- allergic or intolerant to any ingredient found in the study products.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Nutritional ingredient
Dissolve in water and consume with meal
|
Dissolve in water and consume with meals
|
PLACEBO_COMPARATOR: Carbohydrate
dissolve in water and consume with meal
|
dissolve in water and consume with meal
|
EXPERIMENTAL: #1 Nutrtitional ingredient + Fiber
Dissolve in water and consume with meal
|
Dissolve in water and consume with meal
|
EXPERIMENTAL: #2 Nutritional ingredient + Fiber
Dissolve in water and consume with meal
|
Dissolve in water and consume with meal
|
EXPERIMENTAL: #3 Nutritional ingredient + Fiber
Dissolve in water and consume with meal
|
Dissolve in water and consume with meal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Positive AUC from 0 to 240 minutes for plasma glucose.
Time Frame: 0 to 240 minutes
|
0 to 240 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma glucose concentrations
Time Frame: 0 to 240 minutes
|
0 to 240 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (ACTUAL)
September 1, 2010
Study Completion (ACTUAL)
September 1, 2010
Study Registration Dates
First Submitted
March 28, 2011
First Submitted That Met QC Criteria
March 29, 2011
First Posted (ESTIMATE)
March 30, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
March 30, 2011
Last Update Submitted That Met QC Criteria
March 29, 2011
Last Verified
March 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BK92
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Nutritional ingredient
-
Lund UniversityVinnova; Antidiabetic Food Centre AFCCompleted
-
Unilever R&DCompleted
-
University of Notre DameIfakara Health InstituteWithdrawn
-
University of Notre DameCenters for Disease Control and Prevention; Kenya Medical Research InstituteWithdrawn
-
University of Notre DameJohns Hopkins University; Ministry of Health, Zambia; Macha Research Trust, ZambiaWithdrawn
-
University of Notre DameIndonesia-MoHCompleted
-
Unilever R&DCompleted
-
BHB Therapeutics, Ireland LTDCompleted